ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional Results available

Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma

ClinicalTrials.gov ID: NCT01849263

Public ClinicalTrials.gov record NCT01849263. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 7:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2 Trial of Single-Agent Ibrutinib (PCI-32765) in Relapsed or Refractory Follicular Lymphoma

Study identification

NCT ID
NCT01849263
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
41 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 1, 2013
Primary completion
Jun 2, 2016
Completion
Mar 18, 2027
Last update posted
Apr 29, 2026

2013 – 2027

United States locations

U.S. sites
8
U.S. states
6
U.S. cities
7
Facility City State ZIP Site status
Mayo Clinic in Arizona Scottsdale Arizona 85259
Mayo Clinic in Florida Jacksonville Florida 32224-9980
Mayo Clinic in Rochester Rochester Minnesota 55905
Metro Minnesota Community Oncology Research Consortium Saint Louis Park Minnesota 55416
Park Nicollet Clinic - Saint Louis Park Saint Louis Park Minnesota 55416
Washington University School of Medicine St Louis Missouri 63110
Fox Chase Cancer Center Philadelphia Pennsylvania 19111
University of Wisconsin Carbone Cancer Center - University Hospital Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01849263, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 29, 2026 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01849263 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →